Indonesia

Population 2018 268 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
<td>316 (286–345)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–38)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>98 (67–99)</td>
<td>36 (33–37)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases 2.4% (1.8–3.3)
- Previously treated cases 13% (9–18)

TB case notifications, 2018
- Total new and relapse 563 879
  - % tested with rapid diagnostics at time of diagnosis 12%
  - % with known HIV status 37%
  - % pulmonary 88%
  - % bacteriologically confirmed*** 50%
  - % children aged 0–14 years 11%
  - % women 37%
  - % men 52%
- Total cases notified 570 289

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 67% (61–73)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 12% (10–13)

TB/HIV care in new and relapse TB patients, 2018
- Patients with known HIV status who are HIV-positive 10 174 5%
  - on antiretroviral therapy 4 082 40%

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance*** 33%
  - New cases 33%
  - Previously treated cases 127%

Laboratory-confirmed cases* MDR/RR-TB: 9 038, XDR-TB: 80
MDR/RR-TB cases tested for resistance to second-line drugs 2 526

Treatment success rate and cohort size
- New and relapse cases registered in 2017 86% 425 819
- Previous treated cases, excluding relapse, registered in 2017 73% 4 934
- HIV-positive TB cases registered in 2017 69% 7 866
- MDR/RR-TB cases started on second-line treatment in 2016 48% 1 905
- XDR-TB cases started on second-line treatment in 2016 21% 61

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 10% (9.3–11)

TB financing, 2019
- National TB budget (US$ millions) 365
- Funding source: 30% domestic, 13% international, 57% unfunded

* Ranges represent uncertainty intervals
*** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-01-19 Data: www.who.int/tb/data